



Solid Tumor Drug Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-27	124	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Solid Tumor Drug market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Solid Tumor Drug market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Solid Tumor Drug market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Solid Tumor Drug market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Solid Tumor Drug include Johnson & Johnson, Pfizer Inc, GlaxoSmithKline plc., Baxter, AstraZeneca, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Celgene Corporation and Bristol-Myers Squibb Company, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Solid Tumor Drug market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Solid Tumor Drug.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Solid Tumor Drug Market by Company

Johnson & Johnson

Pfizer Inc

GlaxoSmithKline plc.

Baxter

AstraZeneca

F. Hoffmann-La Roche Ltd.

Eli Lilly and Company

Celgene Corporation

Bristol-Myers Squibb Company

Biogen

Amgen Limited & Amgen Ireland Limited

Abbott Laboratories

Solid Tumor Drug Segment by Type

Small Molecules

Biologics

Solid Tumor Drug Segment by Application

Radiology

Neurology

Oncology

Others

Solid Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Solid Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6:

Detailed analysis of Solid Tumor Drug companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Solid Tumor Drug by Type
 - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
 - 2.2.2 Small Molecules
 - 2.2.3 Biologics
- 2.3 Solid Tumor Drug by Application
 - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.3.2 Radiology
 - 2.3.3 Neurology
 - 2.3.4 Oncology
 - 2.3.5 Others
- 2.4 Assumptions and Limitations

3 Solid Tumor Drug Breakdown Data by Type

- 3.1 Global Solid Tumor Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Solid Tumor Drug Forecasted Market Size by Type (2027-2032)

4 Solid Tumor Drug Breakdown Data by Application

- 4.1 Global Solid Tumor Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Solid Tumor Drug Forecasted Market Size by Application (2027-2032)

5 Global Growth Trends

- 5.1 Global Solid Tumor Drug Market Perspective (2021-2032)
- 5.2 Global Solid Tumor Drug Growth Trends by Region
 - 5.2.1 Global Solid Tumor Drug Market Size by Region: 2021 VS 2025 VS 2032
 - 5.2.2 Solid Tumor Drug Historic Market Size by Region (2021-2026)
 - 5.2.3 Solid Tumor Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Solid Tumor Drug Market Dynamics
 - 5.3.1 Solid Tumor Drug Industry Trends
 - 5.3.2 Solid Tumor Drug Market Drivers
 - 5.3.3 Solid Tumor Drug Market Challenges
 - 5.3.4 Solid Tumor Drug Market Restraints

6 Market Competitive Landscape by Players

- 6.1 Global Top Solid Tumor Drug Players by Revenue
 - 6.1.1 Global Top Solid Tumor Drug Players by Revenue (2021-2026)

6.1.2 Global Solid Tumor Drug Revenue Market Share by Players (2021-2026)

6.2 Global Solid Tumor Drug Industry Players Ranking, 2023 VS 2024 VS 2025

6.3 Global Key Players of Solid Tumor Drug Head Office and Area Served

6.4 Global Solid Tumor Drug Players, Product Type & Application

6.5 Global Solid Tumor Drug Manufacturers Established Date

6.6 Global Solid Tumor Drug Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 North America

7.1 North America Solid Tumor Drug Market Size (2021-2032)

7.2 North America Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

7.3 North America Solid Tumor Drug Market Size by Country (2021-2026)

7.4 North America Solid Tumor Drug Market Size by Country (2027-2032)

7.5 United States

7.5 United States

7.6 Canada

7.7 Mexico

8 Europe

8.1 Europe Solid Tumor Drug Market Size (2021-2032)

8.2 Europe Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

8.3 Europe Solid Tumor Drug Market Size by Country (2021-2026)

8.4 Europe Solid Tumor Drug Market Size by Country (2027-2032)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Spain

8.10 Russia

8.11 Netherlands

8.12 Nordic Countries

9 Asia-Pacific

9.1 Asia-Pacific Solid Tumor Drug Market Size (2021-2032)

9.2 Asia-Pacific Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

9.3 Asia-Pacific Solid Tumor Drug Market Size by Country (2021-2026)

9.4 Asia-Pacific Solid Tumor Drug Market Size by Country (2027-2032)

9.5 China

9.6 Japan

9.7 South Korea

9.8 India

9.9 Australia

9.10 China Taiwan

9.11 Southeast Asia

10 South America

10.1 South America Solid Tumor Drug Market Size (2021-2032)

10.2 South America Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

10.3 South America Solid Tumor Drug Market Size by Country (2021-2026)

10.4 South America Solid Tumor Drug Market Size by Country (2027-2032)

10.5 Brazil

10.6 Argentina

10.7 Chile

10.8 Colombia

10.9 Peru

11 Middle East & Africa

11.1 Middle East & Africa Solid Tumor Drug Market Size (2021-2032)

11.2 Middle East & Africa Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

11.3 Middle East & Africa Solid Tumor Drug Market Size by Country (2021-2026)

11.4 Middle East & Africa Solid Tumor Drug Market Size by Country (2027-2032)

11.5 Saudi Arabia

11.6 Israel

11.7 United Arab Emirates

11.8 Turkey

11.9 Iran

11.10 Egypt

12 Players Profiled

12.1 Johnson & Johnson

12.1.1 Johnson & Johnson Company Information

12.1.2 Johnson & Johnson Business Overview

12.1.3 Johnson & Johnson Revenue in Solid Tumor Drug Business (2021-2026)

12.1.4 Johnson & Johnson Solid Tumor Drug Product Portfolio

12.1.5 Johnson & Johnson Recent Developments

12.2 Pfizer Inc

12.2.1 Pfizer Inc Company Information

12.2.2 Pfizer Inc Business Overview

12.2.3 Pfizer Inc Revenue in Solid Tumor Drug Business (2021-2026)

12.2.4 Pfizer Inc Solid Tumor Drug Product Portfolio

12.2.5 Pfizer Inc Recent Developments

12.3 GlaxoSmithKline plc.

12.3.1 GlaxoSmithKline plc. Company Information

12.3.2 GlaxoSmithKline plc. Business Overview

12.3.3 GlaxoSmithKline plc. Revenue in Solid Tumor Drug Business (2021-2026)

12.3.4 GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio

12.3.5 GlaxoSmithKline plc. Recent Developments

12.4 Baxter

12.4.1 Baxter Company Information

12.4.2 Baxter Business Overview

12.4.3 Baxter Revenue in Solid Tumor Drug Business (2021-2026)

12.4.4 Baxter Solid Tumor Drug Product Portfolio

12.4.5 Baxter Recent Developments

12.5 AstraZeneca

12.5.1 AstraZeneca Company Information

12.5.2 AstraZeneca Business Overview

12.5.3 AstraZeneca Revenue in Solid Tumor Drug Business (2021-2026)

12.5.4 AstraZeneca Solid Tumor Drug Product Portfolio

12.5.5 AstraZeneca Recent Developments

12.6 F. Hoffmann-La Roche Ltd.

- 12.6.1 F. Hoffmann-La Roche Ltd. Company Information
- 12.6.2 F. Hoffmann-La Roche Ltd. Business Overview
- 12.6.3 F. Hoffmann-La Roche Ltd. Revenue in Solid Tumor Drug Business (2021-2026)
- 12.6.4 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio
- 12.6.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 12.7 Eli Lilly and Company
 - 12.7.1 Eli Lilly and Company Company Information
 - 12.7.2 Eli Lilly and Company Business Overview
 - 12.7.3 Eli Lilly and Company Revenue in Solid Tumor Drug Business (2021-2026)
 - 12.7.4 Eli Lilly and Company Solid Tumor Drug Product Portfolio
 - 12.7.5 Eli Lilly and Company Recent Developments
- 12.8 Celgene Corporation
 - 12.8.1 Celgene Corporation Company Information
 - 12.8.2 Celgene Corporation Business Overview
 - 12.8.3 Celgene Corporation Revenue in Solid Tumor Drug Business (2021-2026)
 - 12.8.4 Celgene Corporation Solid Tumor Drug Product Portfolio
 - 12.8.5 Celgene Corporation Recent Developments
- 12.9 Bristol-Myers Squibb Company
 - 12.9.1 Bristol-Myers Squibb Company Company Information
 - 12.9.2 Bristol-Myers Squibb Company Business Overview
 - 12.9.3 Bristol-Myers Squibb Company Revenue in Solid Tumor Drug Business (2021-2026)
 - 12.9.4 Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio
 - 12.9.5 Bristol-Myers Squibb Company Recent Developments
- 12.10 Biogen
 - 12.10.1 Biogen Company Information
 - 12.10.2 Biogen Business Overview
 - 12.10.3 Biogen Revenue in Solid Tumor Drug Business (2021-2026)
 - 12.10.4 Biogen Solid Tumor Drug Product Portfolio
 - 12.10.5 Biogen Recent Developments
- 12.11 Amgen Limited & Amgen Ireland Limited
 - 12.11.1 Amgen Limited & Amgen Ireland Limited Company Information
 - 12.11.2 Amgen Limited & Amgen Ireland Limited Business Overview
 - 12.11.3 Amgen Limited & Amgen Ireland Limited Revenue in Solid Tumor Drug Business (2021-2026)
 - 12.11.4 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio
 - 12.11.5 Amgen Limited & Amgen Ireland Limited Recent Developments
- 12.12 Abbott Laboratories
 - 12.12.1 Abbott Laboratories Company Information
 - 12.12.2 Abbott Laboratories Business Overview
 - 12.12.3 Abbott Laboratories Revenue in Solid Tumor Drug Business (2021-2026)
 - 12.12.4 Abbott Laboratories Solid Tumor Drug Product Portfolio
 - 12.12.5 Abbott Laboratories Recent Developments

13 Report Conclusion

14 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Solid Tumor Drug Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Solid Tumor Drug Revenue Market Share by Type (2021-2026)
- Table 7: Global Solid Tumor Drug Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Solid Tumor Drug Revenue Market Share by Type (2027-2032)
- Table 9: Global Solid Tumor Drug Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Solid Tumor Drug Revenue Market Share by Application (2021-2026)
- Table 11: Global Solid Tumor Drug Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Solid Tumor Drug Revenue Market Share by Application (2027-2032)
- Table 13: Global Solid Tumor Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Solid Tumor Drug Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Solid Tumor Drug Market Share by Region (2021-2026)
- Table 16: Global Solid Tumor Drug Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Solid Tumor Drug Market Share by Region (2027-2032)
- Table 18: Solid Tumor Drug Industry Trends
- Table 19: Solid Tumor Drug Industry Drivers
- Table 20: Solid Tumor Drug Industry Opportunities and Challenges
- Table 21: Solid Tumor Drug Market Restraints
- Table 22: Global Top Solid Tumor Drug Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Solid Tumor Drug Revenue Market Share by Players (2021-2026)
- Table 24: Global Solid Tumor Drug Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Solid Tumor Drug, Headquarters and Area Served
- Table 26: Global Solid Tumor Drug Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Solid Tumor Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Solid Tumor Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Solid Tumor Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Solid Tumor Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Solid Tumor Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Solid Tumor Drug Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Solid Tumor Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Solid Tumor Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Solid Tumor Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Solid Tumor Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Solid Tumor Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Johnson & Johnson Company Information
- Table 46: Johnson & Johnson Business Overview
- Table 47: Johnson & Johnson Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 48: Johnson & Johnson Solid Tumor Drug Product Portfolio
- Table 49: Johnson & Johnson Recent Developments
- Table 50: Pfizer Inc Company Information
- Table 51: Pfizer Inc Business Overview
- Table 52: Pfizer Inc Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 53: Pfizer Inc Solid Tumor Drug Product Portfolio
- Table 54: Pfizer Inc Recent Developments
- Table 55: GlaxoSmithKline plc. Company Information

- Table 56: GlaxoSmithKline plc. Business Overview
- Table 57: GlaxoSmithKline plc. Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 58: GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio
- Table 59: GlaxoSmithKline plc. Recent Developments
- Table 60: Baxter Company Information
- Table 61: Baxter Business Overview
- Table 62: Baxter Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 63: Baxter Solid Tumor Drug Product Portfolio
- Table 64: Baxter Recent Developments
- Table 65: AstraZeneca Company Information
- Table 66: AstraZeneca Business Overview
- Table 67: AstraZeneca Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 68: AstraZeneca Solid Tumor Drug Product Portfolio
- Table 69: AstraZeneca Recent Developments
- Table 70: F. Hoffmann-La Roche Ltd. Company Information
- Table 71: F. Hoffmann-La Roche Ltd. Business Overview
- Table 72: F. Hoffmann-La Roche Ltd. Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 73: F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio
- Table 74: F. Hoffmann-La Roche Ltd. Recent Developments
- Table 75: Eli Lilly and Company Company Information
- Table 76: Eli Lilly and Company Business Overview
- Table 77: Eli Lilly and Company Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 78: Eli Lilly and Company Solid Tumor Drug Product Portfolio
- Table 79: Eli Lilly and Company Recent Developments
- Table 80: Celgene Corporation Company Information
- Table 81: Celgene Corporation Business Overview
- Table 82: Celgene Corporation Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 83: Celgene Corporation Solid Tumor Drug Product Portfolio
- Table 84: Celgene Corporation Recent Developments
- Table 85: Bristol-Myers Squibb Company Company Information
- Table 86: Bristol-Myers Squibb Company Business Overview
- Table 87: Bristol-Myers Squibb Company Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 88: Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio
- Table 89: Bristol-Myers Squibb Company Recent Developments
- Table 90: Biogen Company Information
- Table 91: Biogen Business Overview
- Table 92: Biogen Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 93: Biogen Solid Tumor Drug Product Portfolio
- Table 94: Biogen Recent Developments
- Table 95: Amgen Limited & Amgen Ireland Limited Company Information
- Table 96: Amgen Limited & Amgen Ireland Limited Business Overview
- Table 97: Amgen Limited & Amgen Ireland Limited Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 98: Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio
- Table 99: Amgen Limited & Amgen Ireland Limited Recent Developments
- Table 100: Abbott Laboratories Company Information
- Table 101: Abbott Laboratories Business Overview
- Table 102: Abbott Laboratories Revenue in Solid Tumor Drug Business (2021-2026) & (US\$ Million)
- Table 103: Abbott Laboratories Solid Tumor Drug Product Portfolio
- Table 104: Abbott Laboratories Recent Developments
- Table 105: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Solid Tumor Drug Product Image
- Figure 5: Global Solid Tumor Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Solid Tumor Drug Market Share by Type: 2025 VS 2032
- Figure 7: Small Molecules Product
- Figure 8: Biologics Product
- Figure 9: Global Solid Tumor Drug Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 10: Global Solid Tumor Drug Market Share by Application: 2025 VS 2032
- Figure 11: Radiology Product

- Figure 12: Neurology Product
- Figure 13: Oncology Product
- Figure 14: Others Product
- Figure 15: Global Solid Tumor Drug Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 16: Global Solid Tumor Drug Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 17: Global Solid Tumor Drug Market Share by Region: 2025 VS 2032
- Figure 18: Global Solid Tumor Drug Market Share by Players in 2025
- Figure 19: Global Solid Tumor Drug Manufacturers Established Date
- Figure 20: Global Top 5 and 10 Solid Tumor Drug Players Market Share by Revenue in 2025
- Figure 21: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 22: North America Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 23: North America Solid Tumor Drug Market Share by Country (2021-2032)
- Figure 24: United States Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 25: Canada Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 26: Mexico Solid Tumor Drug Market Share by Country (2021-2032)
- Figure 27: Europe Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 28: Europe Solid Tumor Drug Market Share by Country (2021-2032)
- Figure 29: Germany Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 30: France Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 31: U.K. Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: Italy Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 33: Spain Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: Russia Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: Netherlands Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Nordic Countries Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Asia-Pacific Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Asia-Pacific Solid Tumor Drug Market Share by Country (2021-2032)
- Figure 39: China Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 40: Japan Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: South Korea Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: India Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: India Solid Tumor Drug Market Share by Country (2021-2032)
- Figure 44: Australia Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 45: China Taiwan Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: Southeast Asia Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: South America Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: South America Solid Tumor Drug Market Share by Country (2021-2032)
- Figure 49: Brazil Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 50: Argentina Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: Chile Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: Colombia Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 53: Peru Solid Tumor Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Johnson & Johnson Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 55: Pfizer Inc Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 56: GlaxoSmithKline plc. Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 57: Baxter Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 58: AstraZeneca Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 59: F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 60: Eli Lilly and Company Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 61: Celgene Corporation Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 62: Bristol-Myers Squibb Company Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 63: Biogen Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 64: Amgen Limited & Amgen Ireland Limited Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)
- Figure 65: Abbott Laboratories Revenue Growth Rate in Solid Tumor Drug Business (2021-2026)